Generate great Experiance

Generate great Experiance (G2E) is a healthcare technology company specializing in diabetes management solutions. Founded in August 2000 by CEO Chang-beom Jung, a software developer, the company initially focused on building and operating public medical information systems, including for blood and emergency medical services. Over two decades, G2E has leveraged its expertise in IT and medical platforms to transition into developing IoT medical devices.

The company's core offering is the 'DIA:CONN' platform, a brand launched in 2019, which provides a total solution for diabetes care. DIA:CONN, a name derived from 'diabetes' and 'connection', integrates various components to enable real-time, comprehensive blood glucose management. The ecosystem includes the 'Diacon G8' insulin pump, the 'Diacon P8' smart electric insulin pen, and a mobile app that connects with Continuous Glucose Monitors (CGM). This allows patients, guardians, and medical staff to monitor insulin injection data and blood sugar levels in real-time. The platform is utilized in over 90 medical institutions in South Korea, including major hospitals like Seoul National University Hospital and Asan Medical Center.

G2E's business model involves manufacturing and selling these platform-based automatic insulin injectors and providing the associated platform services. Revenue is generated from the sale of devices like the 'Diacon P8' smart insulin pen, for which it has a domestic exclusive distribution agreement with Huons. The company has received significant investment, including a Series A round of 7.5 billion KRW and a Series B round of 8.5 billion KRW, with total accumulated investment reaching approximately 23.5 billion KRW since 2019. G2E is preparing for an IPO with the goal of a listing on the Kosdaq market in 2025 and is also developing an Automated Insulin Delivery (AID) system, aiming to create a complete artificial pancreas system.

Keywords: diabetes management, healthcare platform, insulin pump, smart insulin pen, continuous glucose monitoring, IoT medical device, digital health, blood glucose management, DIA:CONN, automated insulin delivery, remote patient monitoring, medical information systems, chronic disease management, insulin therapy, medtech, Diacon G8, Diacon P8, artificial pancreas system, telehealth, healthcare IT